396 related articles for article (PubMed ID: 24846123)
21. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Desimio MG; Giuliani E; Doria M
Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
[TBL] [Abstract][Full Text] [Related]
23. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
[TBL] [Abstract][Full Text] [Related]
24. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
25. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
26. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
[TBL] [Abstract][Full Text] [Related]
27. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
28. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.
Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A
Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908
[TBL] [Abstract][Full Text] [Related]
29. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.
Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M
J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393
[TBL] [Abstract][Full Text] [Related]
30. Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.
Molfetta R; Quatrini L; Santoni A; Paolini R
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767057
[TBL] [Abstract][Full Text] [Related]
31. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
[TBL] [Abstract][Full Text] [Related]
32. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.
Fuertes MB; Girart MV; Molinero LL; Domaica CI; Rossi LE; Barrio MM; Mordoh J; Rabinovich GA; Zwirner NW
J Immunol; 2008 Apr; 180(7):4606-14. PubMed ID: 18354183
[TBL] [Abstract][Full Text] [Related]
33. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
35. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells].
Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.
Thomas M; Boname JM; Field S; Nejentsev S; Salio M; Cerundolo V; Wills M; Lehner PJ
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1656-61. PubMed ID: 18230726
[TBL] [Abstract][Full Text] [Related]
38. Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
Galitska G; Coscia A; Forni D; Steinbrueck L; De Meo S; Biolatti M; De Andrea M; Cagliani R; Leone A; Bertino E; Schulz T; Santoni A; Landolfo S; Sironi M; Cerboni C; Dell'Oste V
Front Immunol; 2021; 12():532484. PubMed ID: 33897679
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis.
Li K; Mandai M; Hamanishi J; Matsumura N; Suzuki A; Yagi H; Yamaguchi K; Baba T; Fujii S; Konishi I
Cancer Immunol Immunother; 2009 May; 58(5):641-52. PubMed ID: 18791713
[TBL] [Abstract][Full Text] [Related]
40. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
